Vendor qualification for pain management and physical medicine practices
Pain management and physical medicine groups that bring on a new biologics distributor commonly separate the vendor-qualification step from any clinical decision-making. The qualification step asks what a distributor can document: donor screening description, processing timeline, third-party sterility testing, and lot-specific release records.
We supply that documentation directly rather than through a sales call, and we reference the governing regulation, 21 CFR 1271.10, so a practice's compliance lead can read the primary source rather than our summary of it.
Provo
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
41- Pain Medicine
- 16
- Physical Medicine & Rehabilitation
- 25
Setting up a verified account
Accounts are opened against an NPI number checked against the NPPES registry, which keeps ordering restricted to licensed professionals and creates a single record per practice. The intake process is short, and once an account is verified, a practice can request documentation for any product line before placing a first order.
Receiving cold-chain shipments in the Mountain West
Cryopreserved Wharton's jelly formats are kept at -80 C and shipped overnight on dry ice in validated containers. Lyophilized formats are shelf-stable and handled per the product insert included with each lot. Either way, each lot carries its own identifier so a clinic can track use at the patient record level once the product arrives.
Confirming regulatory standing
Whether a given intended use of a Wharton's jelly or exosome product meets the homologous-use and minimal-manipulation criteria in 21 CFR 1271.10 is a determination the clinic and its own counsel need to make. Precision Biologics does not advise on clinical use, dosing, or protocols. We recommend confirming standing with the Utah medical board as part of any new-vendor review, and we make physician-level calls available to walk through documentation, not clinical application.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Can pain management clinics in Provo open an account with Precision Biologics?+
Yes, provided the practice can be verified against an active NPI. Orders are limited to licensed clinics and physicians.
What should our practice ask for before adding a new biologics product?+
Request the certificate of analysis, lot release record, and donor eligibility summary for the specific lot under consideration. These are available to verified accounts.
How is product tracked once it reaches our clinic?+
Each lot carries a unique identifier assigned at processing. Clinics use that identifier to track use at the patient record level on their side.